Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2014

Open Access 01-12-2014 | Research

Visceral adiposity index score indicated the severity of coronary heart disease in Chinese adults

Authors: Lu Han, Kai-li Fu, Jing Zhao, Zhi-hao Wang, Meng-xiong Tang, Jia Wang, Hui Wang, Yun Zhang, Wei Zhang, Ming Zhong

Published in: Diabetology & Metabolic Syndrome | Issue 1/2014

Login to get access

Abstract

Background

Visceral adiposity contributes to cardiometabolic risk, and visceral adiposity index (VAI) had significant correlation with visceral adiposity. We aimed to explore whether VAI was associated with cardiac structure and function and assess the impact of the cut-off points of VAI defining visceral adipose dysfunction (VAD) on the severity of coronary heart disease (CHD).

Methods

A total of 95 patients with CHD were divided into Control (nondiabetic CHD patients) and DM group (diabetic CHD patients). Then the two groups were respectively divided into VAD absent and VAD groups. Clinical, echocardiographic and coronary artery angiographic indexes were acquired to examine in relation to VAI.

Results

A significant increasing trend among the four groups of patients (Control + VAD absent, Control +VAD, DM + VAD absent and DM +VAD groups) were observed for waist circumference (WC), body mass index (BMI), systolic blood pressure (SBP), glucose, VAI and Gensini score (P<0.05 for all). The following variables were associated with VAI: total cholesterol, nonesterified fatty acid, Waist-Hip ratio and SBP. VAI was independently associated with Gensini score.

Conclusions

The extent of CHD was more severe in diabetes, and VAI as a simple indicator of visceral adipose mass was strongly associated with the severity of CHD. The cut-off points of VAI used for defining VAD were more useful in diabetic CHD patients in identifying the severity of CHD.
Literature
1.
go back to reference Bozorgmanesh MR, Hadaegh F, Padyab M, Mehrabi Y, Azizi F: Temporal changes in anthropometric parameters and lipid profile according to body mass index among an adult Iranian urban population. Ann Nutr Metab. 2008, 53: 13-22. 10.1159/000152869.CrossRefPubMed Bozorgmanesh MR, Hadaegh F, Padyab M, Mehrabi Y, Azizi F: Temporal changes in anthropometric parameters and lipid profile according to body mass index among an adult Iranian urban population. Ann Nutr Metab. 2008, 53: 13-22. 10.1159/000152869.CrossRefPubMed
2.
go back to reference Després JP: Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. J Endocrinol Investig. 2006, 29: 77-82. Després JP: Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. J Endocrinol Investig. 2006, 29: 77-82.
3.
go back to reference Flegal KM, Shepherd JA, Looker AC, Graubard BI, Borrud LG, Ogden CL, Harris TB, Everhart JE, Schenker N: Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr. 2009, 89: 500-508. 10.3945/ajcn.2008.26847.PubMedCentralCrossRefPubMed Flegal KM, Shepherd JA, Looker AC, Graubard BI, Borrud LG, Ogden CL, Harris TB, Everhart JE, Schenker N: Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr. 2009, 89: 500-508. 10.3945/ajcn.2008.26847.PubMedCentralCrossRefPubMed
4.
go back to reference Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ: Waist circumference and abdominal saggitaldiameter: best simple anthropometric indices of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994, 73: 460-468. 10.1016/0002-9149(94)90676-9.CrossRefPubMed Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ: Waist circumference and abdominal saggitaldiameter: best simple anthropometric indices of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994, 73: 460-468. 10.1016/0002-9149(94)90676-9.CrossRefPubMed
5.
go back to reference Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study Group: Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010, 33: 920-922. 10.2337/dc09-1825.PubMedCentralCrossRefPubMed Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study Group: Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010, 33: 920-922. 10.2337/dc09-1825.PubMedCentralCrossRefPubMed
6.
go back to reference Liu J, Fox CS, Hickson DA, May WL, Ding J, Carr JJ, Taylor HA: Pericardial fat and echocardiographic measures of cardiac abnormalities: the Jackson Heart Study. Diatetes Care. 2011, 34: 341-346. 10.2337/dc10-1312.CrossRef Liu J, Fox CS, Hickson DA, May WL, Ding J, Carr JJ, Taylor HA: Pericardial fat and echocardiographic measures of cardiac abnormalities: the Jackson Heart Study. Diatetes Care. 2011, 34: 341-346. 10.2337/dc10-1312.CrossRef
7.
go back to reference Bozorgmanesh M, Hadaegh F, Azizi F: Predictive performance of the visceral adiposity index for a visceral adiposity-related risk: type 2 diabetes. Lipids Health Dis. 2011, 10: 88-10.1186/1476-511X-10-88.PubMedCentralCrossRefPubMed Bozorgmanesh M, Hadaegh F, Azizi F: Predictive performance of the visceral adiposity index for a visceral adiposity-related risk: type 2 diabetes. Lipids Health Dis. 2011, 10: 88-10.1186/1476-511X-10-88.PubMedCentralCrossRefPubMed
8.
go back to reference Amato MC, Giordano C, Pitrone M, Galluzzo A: Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 2011, 10: 183-10.1186/1476-511X-10-183.PubMedCentralCrossRefPubMed Amato MC, Giordano C, Pitrone M, Galluzzo A: Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 2011, 10: 183-10.1186/1476-511X-10-183.PubMedCentralCrossRefPubMed
9.
go back to reference Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983, 51: 606-10.1016/S0002-9149(83)80105-2.CrossRefPubMed Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983, 51: 606-10.1016/S0002-9149(83)80105-2.CrossRefPubMed
10.
go back to reference Poulsen MK, Henriksen JE, Dahl J, Johansen A, Gerke O, Vach W, Haghfelt T, Høilund-Carlsen PF, Beck-Nielsen H, Møller JE: Left ventricular diastolic function in type 2 diabetes mellitus prevalence and association with myocardial and vascular disease. Circ: Cardiovasc Imaging. 2010, 3: 24-31. 10.1161/CIRCIMAGING.109.855510. Poulsen MK, Henriksen JE, Dahl J, Johansen A, Gerke O, Vach W, Haghfelt T, Høilund-Carlsen PF, Beck-Nielsen H, Møller JE: Left ventricular diastolic function in type 2 diabetes mellitus prevalence and association with myocardial and vascular disease. Circ: Cardiovasc Imaging. 2010, 3: 24-31. 10.1161/CIRCIMAGING.109.855510.
11.
go back to reference van Domburg RT, op Reimer WS, Hoeks SE, Kappetein AP, Bogers AJ: Three life-years gained from smoking cessation after coronary artery bypass surgery: a 30-year follow-up study. Am Heart J. 2008, 156: 473-476. 10.1016/j.ahj.2008.04.007.CrossRefPubMed van Domburg RT, op Reimer WS, Hoeks SE, Kappetein AP, Bogers AJ: Three life-years gained from smoking cessation after coronary artery bypass surgery: a 30-year follow-up study. Am Heart J. 2008, 156: 473-476. 10.1016/j.ahj.2008.04.007.CrossRefPubMed
12.
go back to reference Ashby DT, Dangas G, Mehran R, Lansky AJ, Fahy MP, Iakovou I, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB: Comparison of one-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers, and nonsmokers. Am J Cardiol. 2002, 89: 221-224. 10.1016/S0002-9149(01)02205-6.CrossRefPubMed Ashby DT, Dangas G, Mehran R, Lansky AJ, Fahy MP, Iakovou I, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB: Comparison of one-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers, and nonsmokers. Am J Cardiol. 2002, 89: 221-224. 10.1016/S0002-9149(01)02205-6.CrossRefPubMed
13.
go back to reference Chiolero A, Faeh D, Paccaud F, Cornuz J: Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2008, 87: 801-809.PubMed Chiolero A, Faeh D, Paccaud F, Cornuz J: Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2008, 87: 801-809.PubMed
14.
go back to reference Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE: Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. Endocrinology. 2009, 150: 5262-5272. 10.1210/en.2009-0603.PubMedCentralCrossRefPubMed Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE: Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. Endocrinology. 2009, 150: 5262-5272. 10.1210/en.2009-0603.PubMedCentralCrossRefPubMed
15.
go back to reference Grove EL: Antiplatelet effect of aspirin in patients with coronary artery disease. Dan Med J. 2012, 59: B4506-PubMed Grove EL: Antiplatelet effect of aspirin in patients with coronary artery disease. Dan Med J. 2012, 59: B4506-PubMed
16.
go back to reference Kaess BM, Pedley A, Massaro JM, Murabito J, Hoffmann U, Fox CS: The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia. 2012, 55: 2622-2630. 10.1007/s00125-012-2639-5.PubMedCentralCrossRefPubMed Kaess BM, Pedley A, Massaro JM, Murabito J, Hoffmann U, Fox CS: The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia. 2012, 55: 2622-2630. 10.1007/s00125-012-2639-5.PubMedCentralCrossRefPubMed
17.
go back to reference Malavazos AE, Morricone L, Marocchi A, Ermetici F, Ambrosi B, Corsi MM: N-terminal pro-B-type natriuretic peptide and echocardiographic abnormalities in severely obese patients: correlation with visceral fat. Clin Chem. 2006, 1211-1213. Malavazos AE, Morricone L, Marocchi A, Ermetici F, Ambrosi B, Corsi MM: N-terminal pro-B-type natriuretic peptide and echocardiographic abnormalities in severely obese patients: correlation with visceral fat. Clin Chem. 2006, 1211-1213.
18.
go back to reference Summer R, Walsh K, Medoff BD: Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions?. Pulm Circ. 2011, 1: 440-447. 10.4103/2045-8932.93542.PubMedCentralCrossRefPubMed Summer R, Walsh K, Medoff BD: Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions?. Pulm Circ. 2011, 1: 440-447. 10.4103/2045-8932.93542.PubMedCentralCrossRefPubMed
Metadata
Title
Visceral adiposity index score indicated the severity of coronary heart disease in Chinese adults
Authors
Lu Han
Kai-li Fu
Jing Zhao
Zhi-hao Wang
Meng-xiong Tang
Jia Wang
Hui Wang
Yun Zhang
Wei Zhang
Ming Zhong
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2014
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-6-143

Other articles of this Issue 1/2014

Diabetology & Metabolic Syndrome 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.